Zacks Investment Research downgraded shares of NATUS MEDICAL (BABY) from OUTPERFORM to NEUTRAL on September 04, 2012, with a target price of $14.60.
Natus Medical Incorporated is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on NATUS MEDICAL (BABY),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment